Oxton, United Kingdom
Oxton, United Kingdom

Time filter

Source Type

Patent
Adaptimmune | Date: 2016-10-12

The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a K_(D )for the said peptide-HLA complex of less than or equal to 1 M and/or have an off-rate (k_(off)) of 110^(3 )S^(1 )or slower.


Patent
Immunocore and Adaptimmune | Date: 2016-09-12

The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs may consist essentially of TCRs which may comprise an alpha chain variable domain from a natural repertoire and a beta chain variable domain from a natural repertoire, wherein the alpha chain variable domain may comprise a TRAV12-2 or a TRAV21 gene product and the beta chain variable domain may comprise a TRBV6 gene product.


Patent
Immunocore and Adaptimmune | Date: 2017-01-18

The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain variable domain from a natural repertoire and a beta chain variable domain from a natural repertoire, wherein the alpha chain variable10 domain comprises a TRAV12-2 or a TRAV21 gene product and the beta chain variable domain comprises a TRBV6 gene product.


Patent
Adaptimmune | Date: 2017-04-05

The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide GLYDGMEHL (SEQ ID NO: 1) derived from the MAGE-A10 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.


Patent
Adaptimmune | Date: 2015-04-17

The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a K_(D )for the said peptide-HLA complex of less than or equal to 1 M and/or have an off-rate (k_(off)) of 110^(3 )S^(1 )or slower.


Patent
Adaptimmune | Date: 2016-01-26

The present invention relates to T cell receptors (TCRs) which bind the HLA-A2 restricted FMNKFIYEI (158-166) peptide epitope derived from Fetoprotein (AFP). Certain preferred TCRs of the invention demonstrate excellent binding characteristics and specificity profiles for this AFP epitope. T cell receptors of the invention may comprise at least one TCR alpha chain variable domain and/or at least one TCR beta chain variable domain, the alpha chain variable domain which may comprise an amino acid sequence that has at least 90% identity to the sequence of amino acid residues 1-112 of SEQ ID No: 2, and/or the beta chain variable domain which may comprise an amino acid sequence that has at least 90% identity to the sequence of amino acid residues 1-112 of SEQ ID No: 3.


Patent
Immunocore and Adaptimmune | Date: 2016-02-17

The present invention provides TCRs having an affinity (K_(D)) of less than or equal to 1M, and/or an off-rate (k_(off)) of 1x10^(-3) S^(-1) or slower, for the SLYNTVATL-HLA-A*0201 complex PROVIDED THAT when the said TCR is presented by cell and comprises SEQ ID NOs: 1 and 2, the cell is not a native T cell. Such TCRs are useful, either alone or associated with a therapeutic agent, for targeting HIV infected cells presenting that complex.


Patent
Adaptimmune | Date: 2015-12-14

The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a K_(D )for the said peptide-HLA complex of less than or equal to 1 M and/or have an off-rate (k_(off)) of 110^(3 )S^(1 )or slower.


The present invention provides a T cell receptor (TCR) having the property of binding to ALWGPDPAAA (derived from human pre-pro insulin (PPI) protein) HLA-A*02 complex and comprising a TCR alpha chain variable domain and a TCR beta chain variable domain. Also provided are nucleic acids encoding the TCR and cells engineered to present the TCR. Therapeutic agents based on TCRs of the invention can be used for the purpose of delivering immunosuppressive agents to beta cells in order to prevent their destruction by CD8^(+) T cells.


The invention provides a method for predicting whether a binding peptide, which binds to a target peptide presented by a Major Histocompatibility Complex (MHC) and is for administration to a subject, has the potential to cross react with another peptide in the subject in vivo. The method comprises the steps of identifying at least one binding motif in the target peptide to which the binding peptide binds; and searching for peptides that are present in the subject that comprise the at least one binding motif and that are not the target peptide. The presence of one or more such peptides indicates that the binding peptide has the potential to cross react in vivo.

Loading Adaptimmune collaborators
Loading Adaptimmune collaborators